RHJA
LFCR icon

Rice Hall James & Associates’s Lifecore Biomedical LFCR Stock Holding History

Rice Hall James & Associates’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-120,400
Closed -$1.48M – 288
2019
Q1 		$1.48M Sell
120,400
-32,485
-21% -$397K 0.05% 228
2018
Q4 		$1.81M Buy
152,885
+46,969
+44% +$645K 0.07% 185
2018
Q3 		$1.52M Sell
105,916
-24,559
-19% -$340K 0.05% 220
2018
Q2 		$1.94M Sell
130,475
-1,100
-0.8% -$15.3K 0.07% 207
2018
Q1 		$1.72M Sell
131,575
-29,144
-18% -$383K 0.07% 205
2017
Q4 		$2.02M Buy
+160,719
New +$2.03M 0.08% 202
2014
Q1 		– Sell
-162,205
Closed -$1.97M – 310
2013
Q4 		$1.97M Buy
162,205
+17,630
+12% +$211K 0.14% 181
2013
Q3 		$1.76M Buy
+144,575
New +$2.02M 0.17% 168

Other funds holding LFCR

NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WC
Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Rice Hall James & Associates's LFCR Position: Q2 2019 in Review

Rice Hall James & Associates sold out of Lifecore Biomedical (LFCR) in Q2 2019, closing a stake of 120,400 shares — an estimated $1.48M sold.

Rice Hall James & Associates first reported a position in LFCR in Q3 2013 and held it in 8 quarters. The position peaked at $2.02M in Q4 2017. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2019.

  • Rice Hall James & Associates reported no remaining Lifecore Biomedical position as of Q2 2019 after selling out during the quarter.
  • Rice Hall James & Associates sold 120,400 Lifecore Biomedical shares in Q2 2019, an estimated $1.48M.
  • Rice Hall James & Associates first reported a position in Lifecore Biomedical in Q3 2013 and held it in 8 quarters.
  • Rice Hall James & Associates's Lifecore Biomedical position peaked at $2.02M in Q4 2017.
  • 99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2019.

Based on Rice Hall James & Associates's 13F filing for Q2 2019, filed 1 Aug 2019.